MABLINK BIOSCIENCES

Mablink Bioscience is a biotechnology company wholly owned subsidiary of Eli Lilly since December 2023 and developing next-generation Antibody-Drug-Conjugates (ADC) based on a proprietary drug-linker platform technology. Its drug-linker technology delivers ADCs with a high payload (DAR of 8-16) that are homogeneous and plasma-stable,without negative impact on aggregation, with improved pharmacokinetics, in a timely and cost-effective manner. With its technology platform, Mablink is democratizing the use of next-generation ADC in the clinic, to improve patient care in the immuno-oncolgy field.